相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment
Jessica R. Wilson et al.
HYPERTENSION (2022)
Sex differences in the lung ACE/ACE2 balance in hypertensive rats
Flavia L. Martins et al.
BIOSCIENCE REPORTS (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice
Ravi Nistala et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)
Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
Acaris Benetti et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)
Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5/6 nephrectomy
Denis Delic et al.
SCIENTIFIC REPORTS (2020)
Postprandial increase in glucagon-like peptide-1 is blunted in severe heart failure
Daniel F. Arruda-Junior et al.
CLINICAL SCIENCE (2020)
Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease
Juliana Isa Beraldo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme
Mohamed Abouelkheir et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge
I. Dicembrini et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)
Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?: Clues From Laboratory Models and Clinical Trials
Milton Packer
CIRCULATION RESEARCH (2018)
Significance of circulatory DPP4 activity in metabolic diseases
Titli Nargis et al.
IUBMB LIFE (2018)
THE ACE2/ANGIOTENSIN-(1-7)/MAS AXIS OF THE RENIN-ANGIOTENSIN SYSTEM: FOCUS ON ANGIOTENSIN-(1-7)
Robson Augusto Souza Santos et al.
PHYSIOLOGICAL REVIEWS (2018)
Worsening Heart Failure During the Use of DPP-4 Inhibitors Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications
Milton Packer
JACC-HEART FAILURE (2018)
Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
John J. V. McMurray et al.
JACC-HEART FAILURE (2018)
Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension
Jiaxi Xu et al.
CIRCULATION RESEARCH (2017)
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin
William B. White et al.
HYPERTENSION (2016)
DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury
Jee Eun Lee et al.
LABORATORY INVESTIGATION (2016)
Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure
Daniel F. Arruda-Junior et al.
FRONTIERS IN PHYSIOLOGY (2016)
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire et al.
JAMA CARDIOLOGY (2016)
Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules
Annayya Aroor et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart
Li-Hui Zhang et al.
CARDIOVASCULAR DRUGS AND THERAPY (2015)
Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial Response
Benjamin M. Scirica et al.
CIRCULATION (2015)
Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
Thiago A. Salles et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome
Alicia A. Thorp et al.
JOURNAL OF DIABETES RESEARCH (2015)
Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Liam M. McCormick et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2014)
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
Prevention of Obesity-Induced Renal Injury in Male Mice by DPP4 Inhibition
Ravi Nistala et al.
ENDOCRINOLOGY (2014)
Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells
Diana Roehrborn et al.
FEBS LETTERS (2014)
Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
Jessica K. Devin et al.
HYPERTENSION (2014)
Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells
Christoph Brenner et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS
Vaibhav B. Patel et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2014)
miR-29b as a Therapeutic Agent for Angiotensin II-induced Cardiac Fibrosis by Targeting TGF-β/Smad3 signaling
Yang Zhang et al.
MOLECULAR THERAPY (2014)
DPP4 Inhibition Attenuates Filtration Barrier Injury and Oxidant Stress in the Zucker Obese Rat
Ravi Nistala et al.
OBESITY (2014)
Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice
Ayako Takahashi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2013)
Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure
Leonardo dos Santos et al.
CIRCULATION-HEART FAILURE (2013)
Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats
Annayya R. Aroor et al.
ENDOCRINOLOGY (2013)
Dipeptidyl peptidase IV and Mortality After an Acute Heart Failure Episode
Patricia Lourenco et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
Toshimasa Shigeta et al.
CIRCULATION (2012)
Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
Nelson Gomez et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
William B. White et al.
AMERICAN HEART JOURNAL (2011)
Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats
Bruna P. M. Pacheco et al.
JOURNAL OF HYPERTENSION (2011)
Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1
Renato O. Crajoinas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2011)
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
Philip A. Read et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2010)
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
Meghan Sauve et al.
DIABETES (2010)
Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction
Marc-Michael Zaruba et al.
CELL STEM CELL (2009)
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Nancy J. Brown et al.
HYPERTENSION (2009)
Left Ventricle Radio-frequency Ablation in the Rat: A New Model of Heart Failure due to Myocardial Infarction Homogeneous in Size and Low in Mortality
Ednei L. Antonio et al.
JOURNAL OF CARDIAC FAILURE (2009)
The Sympathetic Nervous System in Heart Failure Physiology, Pathophysiology, and Clinical Implications
Filippos Triposkiadis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema
James Brian Byrd et al.
HYPERTENSION (2008)
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
Eva van Rooij et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice
Gavin Y. Oudit et al.
CARDIOVASCULAR RESEARCH (2007)
Mechanisms of sympathetic activation in obesity-related hypertension
Murray Esler et al.
HYPERTENSION (2006)
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
CM Ferrario et al.
CIRCULATION (2005)
Myocardial infarction increases ACE2 expression in rat and humans
LM Burrell et al.
EUROPEAN HEART JOURNAL (2005)
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors
Y Ishiyama et al.
HYPERTENSION (2004)
分享论文
